Anemia, Anemia in pregnancy, Ferric carboxymaltose, Iron-deficiency anemia and IV iron, Iron sucrose
Citation Information :
Bharadwaj MK, Patrikar S, Singh Y. Comparative Analysis of Injection Ferric Carboxymaltose vs Iron Sucrose for Treatment of Iron-deficiency Anemia in Pregnancy: Systematic Review and Meta-analysis. J South Asian Feder Obs Gynae 2023; 15 (5):629-636.
Aim: Anemia is a serious global health problem amongst pregnant women with iron-deficiency being the most common cause. This adversely impacts the outcome of pregnancy in both the mother and the fetus. Oral iron has been the standard of care for treatment for this condition but due to its potential for severe adverse effects sometimes parenteral iron complexes have an important role as the newer complexes have a higher efficacy and safety profile.
Background: Both intravenous iron sucrose (IS) vs ferric carboxymaltose (FCM) are interchangeably used for the treatment of iron-deficiency anemia (IDA) in pregnancy when oral iron is not tolerated but the superiority of one over the other is equivocal.
Result: After a comprehensive literature search as per PRISMA guidelines 22 studies (3 randomized trials and 19 observational) revealed a significantly higher rise in hemoglobin [standardized mean difference of 0.59 gm/dL (95% confidence interval 0.26–0.93 gm/dL) in favor of carboxymaltose group (p = 0.001)] and ferritin levels [standardized mean difference of 54.85 µg/L (95% confidence interval 36.33–74.37 µg/L) in favor of carboxymaltose group (p = 0.001)] along with lesser adverse effects with FCM as compared to IS [26% lesser with FCM vis-a-vis IS group (p = 0.001)].
Conclusion: Both intravenous IS vs FCM are interchangeably used for the treatment of IDA in pregnancy when oral iron is not tolerated. Ferric carboxymaltose has an upper edge over IS due to a higher rise of hemoglobin and ferritin levels along with lesser adverse effects and also its convenience in use. However, side-effects of the FCM need to be analyzed more definitively to convincingly accept its superiority in the treatment of IDA in pregnancy.
WHO. Prevalence of anaemia in pregnant women (aged 15–49) (%). 2021. Available from: https://www.who.int/data/gho/data/indicators/indicator-details/GHO/prevalence-of-anaemia-in-pregnant-women-(-). Accessed on: 20 Nov 2021.
Srour MA, Aqel SS, Srour KM, et al. Prevalence of anemia and iron deficiency among Palestinian pregnant women and its association with pregnancy outcome. Anaemia 2018;2018:1–7. DOI: 10.1155/2018/9135625.
Zhang Q, Lu XM, Zhang M, et al. Adverse effects of iron deficiency anemia on pregnancy outcome and offspring development and intervention of three iron supplements. Sci Rep 2021;11(1):1347. DOI: 10.1038/s41598-020-79971-y.
Tolkien Z, Stecher L, Mander AP, et al. Ferrous sulphate supplementation causes significant gastrointestinal side-effects in adults: A systematic review and meta-analysis. PLoS One 2015; 10(2):e0117383. DOI: 10.1371/journal.pone.0117383.
Shah AA, Donovan K, Seeley C, et al. Risk of infection associated with administration of intravenous iron: A systematic review and meta-analysis. JAMA Netw Open 2021;4(11):e2133935. DOI: 10.1001/jamanetworkopen.2021.33935.
Garzon S, Cacciato PM, Certelli C, et al. Iron deficiency anemia in pregnancy: Novel approaches for an old problem. Oman Med J 2020;35(5):e166–166. DOI: 10.5001/omj.2020.108.
Api O, Breyman C, Çetiner M, et al. Diagnosis and treatment of iron deficiency anemia during pregnancy and the postpartum period: Iron deficiency anemia working group consensus report. Turk J Obstet Gynecol 2015;12(3):173–181. DOI: 10.4274/tjod.01700.
Breymann C, Honegger C, Hösli I, et al. Diagnosis and treatment of iron-deficiency anaemia in pregnancy and postpartum. Arch Gynecol Obstet 2017;296(6):1229–1234. DOI: 10.1007/s00404-017-4526-2.
Sterne JA, Hernán MA, Reeves BC, et al. ROBINS-I: A tool for assessing risk of bias in non-randomised studies of interventions. BMJ 2016;355:i4919. DOI: 10.1136/bmj.i4919.
Joshi SD, Chikkagowdra S, Kumar VCM. Comparative study of efficacy and safety of intravenous ferric carboxy maltose versus IS in treatment of postpartum iron deficiency anemia. Int J Reprod Contracept Obstet Gynecol 2016;5(8):2566–2570. DOI: http://dx.doi.org/10.18203/2320-1770.ijrcog20162199.
Garg R, Nigam A, Agrawal P, et al. Iron carboxymaltose: A safe and effective molecule to combat anemia in pregnancy. Int J Curr Res Aca Rev 2016;4(2):124–130. DOI: 10.20546/ijcrar.2016.402.015.
Christoph P, Schuller C, Studer H, et al. Intravenous iron treatment in pregnancy: Comparison of high-dose FCM vs. IS. J Perinat Med 2012;40(5):469–474. DOI: 10.1515/jpm-2011-0231.
Boughton S, Chen L, Kidson-Gerber G, et al. Intravenous IS and FCM in pregnant patients: An observational study of maternal efficacy and tolerance. Journal of Pharmacy Practice and Research 2017;47(6):419–425. DOI: 10.1002/jppr.1265.
Mahajan A, Bhagat B R, Gupta S, et al. A comparative study of efficacy and safety of intravenous FCM versus IS in the treatment of iron deficiency anaemia of pregnancy in a tertiary care hospital. Int J Reprod Contracept Obstet Gynecol 2018;7(5):1938–1942. DOI: https://doi.org/10.18203/2320-1770.ijrcog20181933.
Shah S, Swapna K. A comparative study of efficacy and safety of intravenous FCM versus intravenous is in the treatment of iron deficiency anaemia of pregnancy. IOSR Journal of Dental and Medical Sciences (IOSR-JDMS) 2018;17(9):13–17. DOI: 10.9790/0853-1709031317.
Yasodha S, Swetha T, Prabhu Ravi. Comparative study of efficacy and safety of anaemia correction between IS vs FCM in pregnancy. IOSR Journal of Dental and Medical Sciences (IOSR-JDMS) 2019;18(6):45–48. DOI: 10.9790/0853-1806034548.
Khan S, Gupta S. A comparative study of injection FCM and IS in anaemia complicating pregnancy. International Journal of Contemporary Medical Research 2019;6(8):H6–H9. DOI: http://dx.doi.org/10.21276/ijcmr.2019.6.8.20.
Verma P, Roy D, Suman S. Comparison between FCM and IS in pregnant women with iron deficiency anaemia. International Journal of Scientific Research 2020;9(1):20–21. DOI: 10.36106/ijsr.
Maheshwari B, Mahtab V, Tyagi S, et al. Evaluation of efficacy, safety and cost effectiveness of oral iron and injectable IS and ferric carboxy maltose in pregnant women in 2nd and 3rd trimester in anaemia. Indian J Obstet Gynecol Res 2017;4(1):96–100. DOI: 10.18231/2394-2754.2017.0022.
Metgud MC, Metgud SB, Bellad MB, et al. Comparison of efficacy and safety of intravenous FCM vs IS in the treatment of antepartum iron deficiency anemia: A randomized controlled trial. Malhotra J, editor. Journal of SAFOG 2016;8(4):314–318. DOI: 10.5005/jp-journals-10006-1441.
Jose A, Mahey R, Sharma JB, et al. Comparison of FCM and IS complex for treatment of iron deficiency anemia in pregnancy - Randomised controlled trial. BMC Pregnancy Childbirth 2019;19(1):54. DOI: 10.1186/s12884-019-2200-3.
Ganzoni AM. Intravenous iron-dextran: Therapeutic and experimental possibilities. Schweiz Med Wochenschr 1970;100(7):301–303. PMID: 5413918.
Shi Q, Leng W, Wazir R, et al. Intravenous IS versus oral iron in the treatment of pregnancy with iron deficiency anaemia: A systematic review. Gynecol Obstet Invest 2015;80(3):170–178. DOI: 10.1159/000376577.
Burwick RM, Govindappagari S. Treatment of iron deficiency anemia in pregnancy with intravenous versus oral iron: Systematic review and meta-analysis. Am J Perinatol 2018;36(04):366–376. DOI: 10.1055/s-0038-1668555.
Sultan P, Bampoe S, Shah R, et al. Oral versus intravenous iron therapy for postpartum anemia: A systematic review and meta-analysis. Obstetric Anesthesia Digest 2020;40(2):60–61. DOI: 10.1097/01aoa.0000661312.93260.11.
Rogozińska E, Daru J, Nicolaides M, et al. Iron preparations for women of reproductive age with iron deficiency anaemia in pregnancy (FRIDA): A systematic review and network meta-analysis. Lancet Haematol 2021;8(7):e503–e512. DOI: https://doi.org/10.1016/S2352-3026(21)00137-X.
Kulnigg S, Stoinov S, Simanenkov V, et al. A novel intravenous iron formulation for treatment of anemia in inflammatory bowel disease: The FCM (FERINJECT) randomized controlled trial. Am J Gastroenterol 2008;103(5):1182–1192. DOI: 10.1111/j.1572-0241.2007.01744.x.
Barish CF, Koch T, Butcher A, et al. Safety and efficacy of intravenous FCM (750 mg) in the treatment of iron deficiency anemia: Two randomized, controlled trials. Anemia 2012;2012:1–9. DOI: 10.1155/2012/172104.
Qassim A, Mol BW, Grivell RM, et al. Safety and efficacy of intravenous iron polymaltose, IS and FCM in pregnancy: A systematic review. Aust N Z J Obstet Gynaecol 2017;58(1):22–39. DOI: 10.1111/ajo.12695.
Shin HW, Go DY, Lee SW, et al. Comparative efficacy and safety of intravenous FCM and IS for iron deficiency anemia in obstetric and gynecologic patients. Medicine (Baltimore) 2021;100(20):e24571. DOI: 10.1097/MD.0000000000024571.
Rognoni C, Venturini S, Meregaglia M, et al. Efficacy and safety of FCM and other formulations in iron-deficient patients: A systematic review and network meta-analysis of randomised controlled trials. Clinical Drug Investigation 2015;36(3):177–194. DOI: 10.1007/s40261-015-0361-z.
Auerbach M, Deloughery T. Single-dose intravenous iron for iron deficiency: A new paradigm. Hematology Am Soc Hematol Educ Program 2016;2016(1):57–66. DOI: 10.1182/asheducation-2016.1.57.
Avni T, Bieber A, Grossman A, et al. The safety of intravenous iron preparations. Mayo Clin Proc 2015;90(1):12–23. DOI: 10.1016/j.mayocp.2014.10.007.
Haider BA, Olofin I, Wang M, et al. Anaemia, prenatal iron use, and risk of adverse pregnancy outcomes: Systematic review and meta-analysis. BMJ 2013;346:f3443. DOI: https://doi.org/10.1136/bmj. f3443.
Greiner K, Caughey AB, Butwick AJ. 292: IV versus oral iron for postpartum anemia: A cost-effectiveness analysis. American Journal of Obstetrics and Gynecology 2020;222(1):S197. DOI: https://doi.org/10.1016/j.ajog.2019.11.308.
Aksan A, Beales ILP, Baxter G, et al. Evaluation of the cost-effectiveness of iron formulations for the treatment of iron deficiency anaemia in patients with inflammatory bowel disease in the UK. Clinicoecon Outcomes Res 2021;13:541–552. DOI: https://doi.org/10.2147/CEOR.S306823.
Evstatiev R, Marteau P, Iqbal T, et al. FERGI cor, a randomized controlled trial on FCM for iron deficiency anemia in inflammatory bowel disease. Gastroenterology 2011;141(3):846–853.e12. DOI: 10.1053/j.gastro.2011.06.005.
Subramanian R, Khardori R. Severe hypophosphatemia: Pathophysiologic implications, clinical presentations, and treatment. Medicine (Baltimore) 2000;79(1):1–8. DOI: 10.1097/00005792- 200001000-00001.
Wolf M, Rubin J, Achebe M, et al. Effects of iron isomaltoside vs FCM on hypophosphatemia in iron-deficiency anemia: Two randomized clinical trials. JAMA 2020;323(5):432–443. DOI: 10.1001/jama.2019.22450.
Zoller H, Schaefer B, Glodny B. Iron-induced hypophosphatemia: An emerging complication. Curr Opin Nephrol Hypertens 2017;26(4):266–275. DOI: 10.1097/MNH.0000000000000329.
Schaefer B, Tobiasch M, Viveiros A, et al. Hypophosphataemia after treatment of iron deficiency with intravenous FCM or iron isomaltoside—a systematic review and meta-analysis. Br J Clin Pharmacol 2020;87(5):2256–2273. DOI: 10.1111/bcp.14643.